Track startup funding.
Find the investors behind it.
A practical, source-backed view of funding rounds, VC firms, and the companies they back — built for faster founder and investor research.
- Nov 16 Stark Future closes financing with more than €150M total transaction value at €1.2B pre-money valuation
- Nov 16 Seawolf Therapeutics discloses $100M total across Seed and Series A, announces separate Sanofi pact
- Nov 16 Corma raises $125M Series A led by NEA at reported $1B valuation
- Nov 16 Johnson & Johnson agrees to acquire Ollin for $2.2B upfront plus up to $1.125B milestones
- Nov 16 Lilly agrees to buy Calytrix Bio for up to $1.5B including contingent clinical milestones
- Nov 16 Remedy Robotics announces $62M Series B led by DCVC for investigational N1 system
Coverage snapshot
Know what’s in the dataset.
A growing research layer across funds, companies, and source-backed venture coverage.
862
VC firms
Profiles with stage, focus, and contact links.
2,186
Startups
Companies appearing in our funding coverage.
6
Latest signals
Fund closes and rounds in the investment feed.
1,492
Research articles
Analysis, explainers, and market roundups.
Latest funding & fund-close signals
A date-first view of the newest entries in the Venture Capital Tracker feed. Open each item for the full context and source trail.
Stark Future closes financing with more than €150M total transaction value at €1.2B pre-money valuation
Issuer and participating investor on Nov 16 confirmed a CLOSED financing transaction with MORE THAN €150M in TOTAL transaction value, led by Highland Europe with Morgan Stanley 1GT and Axon. Company reports €1.2B PRE-money valuation. Breakdown between fresh primary company cash and potential secondary or other deal components was NOT disclosed. A possible second closing remains uncompleted. Product is a commercial VARG electric motorcycle range, not a preclinical concept. €150M is a strict lower bound on deal value, not precise cash raised.
Seawolf Therapeutics discloses $100M total across Seed and Series A, announces separate Sanofi pact
Seawolf publicly emerged November 16, 2026, disclosing $100M cumulatively raised in a Versant-led seed followed by a Series A involving Versant, MPM BioImpact, Novartis Venture Fund and others. Individual seed/A amounts and legal closing days are undisclosed; this is ONE combined historical disclosure, not a $100M Series A. A distinct Sanofi research/license arrangement includes up to $1.2B conditional milestones and royalties, NOT $1.2B startup financing, initial cash or company valuation. TRIDENT DNA-LNP clinical results remain preclinical.
Corma raises $125M Series A led by NEA at reported $1B valuation
Issuer-announced November 16, 2026 Series A of $125M led by New Enterprise Associates; existing investors Sequoia, Khosla Ventures and Coatue participated. The company reports $185M cumulative disclosed equity funding after its separate August $60M seed. The $1B valuation's pre/post-money basis and precise closing day are not specified; company claims about autonomous security outcomes are unverified commercial metrics.
Johnson & Johnson agrees to acquire Ollin for $2.2B upfront plus up to $1.125B milestones
Nov 16 definitive acquisition agreement, not yet legally closed. $2.2B cash upfront plus up to approximately $1.125B in future regulatory and commercial payments; maximum contingent transaction consideration about $3.325B. Separately Blackstone will fund $750M toward J&J's Phase 3 program across multiple years for milestones and royalties. That development funding is NOT acquisition consideration or new Ollin equity. OLN324 investigational; close targeted before end of 2026.
Lilly agrees to buy Calytrix Bio for up to $1.5B including contingent clinical milestones
Definitive agreement announced November 16, not completed acquisition. Maximum possible $1.5B cash to Calytrix shareholders comprises undisclosed upfront consideration and additional clinical/regulatory milestone payments. Actual upfront, certainty of milestones, and legal close date undisclosed. Calytrix remains private pending confirmed close.
Remedy Robotics announces $62M Series B led by DCVC for investigational N1 system
Company-disclosed $62M Series B for pivotal clinical study preparation, FDA regulatory pathway and N1 prototypes. DCVC leads; UC Investments, Skip Capital, Hostplus and existing backers participate. N1 is investigational, not commercially available or approved. Legal financing closing date and valuation undisclosed.
Research desk
Latest venture capital research
Hyperbolic Raises $30M: GPU Compute Grid, RunPod Rivals and Funding Economics
Hyperbolic's $30M Walden-led Series A1, Forge GPU orchestration, planned compute marketplace, RunPod/Vast comparisons and true GPU-cloud costs.
Read articleSiena AI Raises $17M: Agent of Record, Pricing, Investors and Real Support ROI
Siena AI's $17M Series A, York IE lead, Agent of Record strategy and $750 + $0.90/ticket pricing explained with buyer ROI checks.
Read articleWabi Raises $55M at $1.25B: Investors, AI Mini-Apps and the Agent Pivot
Wabi's $55M IVP-led financing, $1.25B valuation, Replika founder, mini-app pivot, investors, product positioning and retention risks.
Read articleTorus $500M Funding: Foundry AI Data Centers, Power Constraints and Reality Check
Torus announced $500M growth capital for modular Foundry AI compute. Analyze 12–16-week deployment, 1–20 MW sites, grid constraints, funding structure and realistic milestones.
Read articleGo deeper
Research the market your way.
Use the structured pages when you need a shortlist, a company read, or a plain-English answer about how venture capital works.